logo

For the Inventor, By the Inventor

Morris Plains, NJ, United States of America

Ibc Pharmaceuticals, Inc.


USPTO Granted Patents = 72



Forward Citations = 1,879

Loading Chart...
Loading Chart...

13 inventors (with patents filed for the assignee):

goldMedal David M Goldenberg (69 out of 393 patents)

silverMedal Chien-Hsing Chang (66 out of 140 patents)

bronzeMedal Edmund A Rossi (52 out of 77 patents)

4.  William John McBride (22 out of 85 patents)

5.  Diane Rossi (11 out of 13 patents)

6.  Chien Hsing Chang (4 out of 8 patents)

7.  Hans J Hansen (3 out of 191 patents)

8.  Rongxiu Li (3 out of 3 patents)

9.  Donglin Liu (2 out of 5 patents)

10.  Serengulam V Govindan (1 out of 112 patents)

11.  Fernando Jose Rebelo Do Couto (1 out of 31 patents)

12.  Roberto L Ceriani (1 out of 17 patents)

13.  Jerry A Peterson (1 out of 1 patent)

14.  William J Mcbride (0 patent)

15.  Chien-Hsing Ken Chang (0 patent)


Core Competencies:
Trop-2 Immunotherapy
Bispecific Antibodies
Dock-and-Lock Technology
Cytokine Therapeutics
Immunoconjugates
Combination Therapy
Interferon Lambda
Multivalent Antibody Complexes
HIV Therapy
Immunotoxins
Cancer Vaccines
Autoimmune Disease Treatment

72 patents:

1. 10662252 - Disease therapy by inducing immune response to Trop-2 expressing cells (2020-05-26),
2. 10385139 - Murine, chimeric, humanized or human anti-TNF-alpha antibodies (2019-08-20),
3. 10308688 - T-cell redirecting bispecific antibodies for treatment of disease (2019-06-04),
4. 10280220 - Immunoconjugates with an intracellularly-cleavable linkage (2019-05-07),
5. 10245321 - Combination therapy for inducing immune response to disease (2019-04-02),
6. 10239938 - T-cell redirecting bispecific antibodies for treatment of disease (2019-03-26),
7. 10183992 - T-cell redirecting bispecific antibodies for treatment of disease (2019-01-22),
8. 10131712 - Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors (2018-11-20),
9. 10111954 - Combination therapy for inducing immune response to disease (2018-10-30),
10. 10022427 - Interferon lambda-antibody complexes (2018-07-17),
11. 9932413 - Murine, chimeric, humanized or human anti-IL-6 antibodies (2018-04-03),
12. 9931413 - Tetrameric cytokines with improved biological activity (2018-04-03),
13. 9879088 - Disease therapy by inducing immune response to Trop-2 expressing cells (2018-01-30),
14. 9872920 - PEGylation by the dock and lock (DNL) technique (2018-01-23),
15. 9862770 - Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors (2018-01-09),
IBC Pharmaceuticals, Inc. is a leading biopharmaceutical company specializing in the development and commercialization of innovative therapies. With a strong focus on research and development, we strive to improve patients' lives by bringing advanced treatments to market. Our team of dedicated scientists and professionals work tirelessly to discover and develop novel drugs, with a particular emphasis on oncology and immunology. Continuous innovation, cutting-edge technologies, and a commitment to integrity are the foundations of our success.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

72 Patents

#4 in Morris Plains, NJ

#221 in New Jersey

#4,879 in US

#9,952 in the World

...
Morris Plains, NJ, United States of America

Ibc Pharmaceuticals, Inc.

Forward Citations = 1,879

13 inventors:

goldMedal David M Goldenberg (69 out of 393 patents)

silverMedal Chien-Hsing Chang (66 out of 140 patents)

bronzeMedal Edmund A Rossi (52 out of 77 patents)

4.  William John McBride (22 out of 85 patents)

5.  Diane Rossi (11 out of 13 patents)

Please report any incorrect information to support@idiyas.com
Loading…